BioSpace News Archive

Oncocyte Corporation, a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, announced that Ronnie Andrews will step down from his role as Chief Executive Officer and as a director of the Company’s board of directors effective December 1, 2022.

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today reported preliminary dose-ranging data from the first two dose levels of the dose escalation part of the Phase 1b/2 study of Nana-val in patients with EBV+ recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).

The phase 3 trial results for lecanemab and gantenerumab presented at the Clinical Trials on Alzheimer’s Disease conference demonstrate why optimal treatment of Alzheimer’s will require drugs that do more than clear amyloid plaques.

Ferring Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) approved REBYOTA® (fecal microbiota, live-jslm), a novel first-in-class microbiota-based live biotherapeutic indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI.

Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, announced it granted inducement awards on November 30, 2022.

SK Biopharmaceuticals, an innovative global pharmaceutical company, announced that it has named Mr. Donghoon Lee, Executive Vice President and Head of Bio Investment Center of SK Inc., as the new Chief Executive Officer and President of SK Biopharmaceuticals and its U.S. subsidiary SK Life Science.

Liminatus Pharma LLC and Iris Acquisition Corp announced they have entered into a definitive business combination agreement.

Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, announced the pricing of an underwritten public offering of 6,550,219 shares of its common stock at a public offering price of $45.80 per share.